Post-eradication poliovirus facility-associated community risks

被引:13
|
作者
Dowdle, Walter R.
Wolff, Chris
机构
[1] Task Force Child Survial & Dev, Decatur, GA 30030 USA
[2] WHO, Vaccine Assessment & Monitoring, CH-1211 Geneva 27, Switzerland
关键词
poliovirus containment; community risks; transmission risks; laboratory containment;
D O I
10.1016/j.biologicals.2006.03.003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Minimizing the risk of poliovirus transmission from the poliovirus facility to an increasingly susceptible community is crucial when global poliovirus transmission and OPV use stops. Community risks of exposure to wild poliovirus as well as Sabin strains are highest from facility personnel who are unknowingly contaminated or infected. Immunization with OPV or IPV prevents poliomyelitis, but neither vaccine fully inhibits silent infection of the gut. Facility environments maintained at low relative humidity (< 50%) may reduce poliovirus survival and inhalation risk. Circulating antibodies reduce personnel infection risks from injection or virus entry through breaks in skin or mucous membranes. Community exposure risk through inhalation of contaminated air effluent is likely low in most modern facilities. Community risks through ingestion of liquid effluents are facility-specific and may range from high to low. This assessment of community risks, when combined with assessments of facility-specific hazards and the consequences of wild or Sabin poliovirus transmission, provides the foundation for effective risk management. (c) 2006 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 50 条
  • [41] Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
    Tebbens, Radboud J. Duintjer
    Pallansch, Mark A.
    Kew, Olen M.
    Caceres, Victor M.
    Jafari, Hamid
    Cochi, Stephen L.
    Sutter, Roland W.
    Aylward, R. Bruce
    Thompson, Kimberly M.
    RISK ANALYSIS, 2006, 26 (06) : 1471 - 1505
  • [42] Complications of Hospital-Onset Healthcare Facility-Associated Clostridium difficile Infections Among Veterans
    Evans, Martin E.
    Kralovic, Stephen M.
    Simbartl, Loretta A.
    Whitlock, Judith L.
    Jain, Rajiv
    Roselle, Gary A.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2016, 37 (06): : 717 - 719
  • [43] Impact of Change to Molecular Testing for Clostridium difficile Infection on Healthcare Facility-Associated Incidence Rates
    Moehring, Rebekah W.
    Lofgren, Eric T.
    Anderson, Deverick J.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (10): : 1055 - 1061
  • [44] A Pilot Study: the Development of a Facility-Associated Microbiome and Its Association with the Presence of Listeria Spp. in One Small Meat Processing Facility
    Belk, Aeriel D.
    Frazier, A. Nathan
    Fuerniss, Luke K.
    Delmore, Robert
    Belk, Keith
    Borlee, Brad
    Geornaras, Ifigenia
    Martin, Jennifer N.
    Metcalf, Jessica L.
    MICROBIOLOGY SPECTRUM, 2022, 10 (05):
  • [45] Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals
    Miller, Becky A.
    Chen, Luke F.
    Sexton, Daniel J.
    Anderson, Deverick J.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2011, 32 (04): : 387 - 390
  • [46] POST-ERADICATION RETESTING FOR HELICOBACTER PYLORI INFECTION IN PATIENTS UNDERGOING UPPER GASTRO-INTESTINAL ENDOSCOPY: COMPLIANCE WITH GUIDELINES
    Alradhawi, Mohammad
    Zakeri, Nekisa
    Negus, Rupert
    Mack, Damien
    Morgan, Marsha Y.
    GUT, 2021, 70 : A139 - A139
  • [47] Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update
    Slimings, Claudia
    Riley, Thomas, V
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (07) : 1676 - 1688
  • [48] Using Molecular Characterization to Support Investigations of Aquatic Facility-Associated Outbreaks of Cryptosporidiosis - Alabama, Arizona, and Ohio, 2016
    Hlavsa, Michele C.
    Roellig, Dawn M.
    Seabolt, Matthew H.
    Kahler, Amy M.
    Murphy, Jennifer L.
    McKitt, Taishayla K.
    Geeter, Evelyn F.
    Dawsey, Ron
    Davidson, Sherri L.
    Kim, Thuy N.
    Tucker, Theresa H.
    Iverson, Sally Ann
    Garrett, Brenna
    Fowle, Nicole
    Collins, Jennifer
    Epperson, Gregory
    Zusy, Scott
    Weiss, Joli R.
    Komatsu, Ken
    Rodriguez, Edwin
    Patterson, J. Gage
    Sunenshine, Rebecca
    Taylor, Brandi
    Cibulskas, Katie
    Denny, Lynn
    Omura, Keoni
    Tsorin, Boris
    Fullerton, Kathleen E.
    Xiao, Lihua
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (19): : 493 - 497
  • [49] Accuracy of the H-pylori stool antigen test in the pre- and post-eradication assessment and in patients on omeprazole treatment.
    Manes, G
    Balzano, A
    Iaquinto, G
    Ricci, C
    Giardullo, N
    Lioniello, M
    Piccirillo, MM
    Todisco, A
    Vaira, D
    GUT, 2000, 47 : A113 - A113
  • [50] Association of antibiotic type utilization and duration of antibiotic use with healthcare facility-onset, healthcare facility-associated (HO-HCFA) clostridium difficile infection
    Julius Navarro, Marc
    Isabel De Ocampo, Sherrie
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 415 - 415